101 related articles for article (PubMed ID: 18986464)
1. How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash?
Cholongitas E; Kokolakis G; Ioannidou D
Int J Dermatol; 2008 Nov; 47(11):1203-4. PubMed ID: 18986464
[No Abstract] [Full Text] [Related]
2. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
3. Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
Lin NU; Kasparian E; Morganstern DE; Beard C
J Clin Oncol; 2009 Dec; 27(34):e218-9. PubMed ID: 19786662
[No Abstract] [Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Seiverling EV; Fernanadez EM; Adams D
J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
[TBL] [Abstract][Full Text] [Related]
5. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer G; Brudler O; Heinrich B; Bangerter M
MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
[No Abstract] [Full Text] [Related]
6. Trichomegaly following treatment with gefitinib (ZD1839).
Pascual JC; Bañuls J; Belinchon I; Blanes M; Massuti B
Br J Dermatol; 2004 Nov; 151(5):1111-2. PubMed ID: 15541102
[No Abstract] [Full Text] [Related]
7. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
[TBL] [Abstract][Full Text] [Related]
8. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
9. "Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors.
Cheng PS; Lai FJ
J Am Acad Dermatol; 2013 Sep; 69(3):489-92. PubMed ID: 23957978
[No Abstract] [Full Text] [Related]
10. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Pascual JC; Belinchón I; Sivera F; Yuste A
Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
[No Abstract] [Full Text] [Related]
11. Erlotinib-induced skin manifestations.
Motoki T; Mitsuishi T; Kawana S
J Dermatol; 2009 Dec; 36(12):658-9. PubMed ID: 19958452
[No Abstract] [Full Text] [Related]
12. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Wnorowski AM; de Souza A; Chachoua A; Cohen DE
Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib-associated dermatological toxicity.
Mumoli N; Cei M; Vitale J
QJM; 2013 Apr; 106(4):363-4. PubMed ID: 22927541
[No Abstract] [Full Text] [Related]
14. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Lübbe J; Masouyé I; Dietrich PY
Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
[TBL] [Abstract][Full Text] [Related]
15. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Treudler R; Zouboulis CC
Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
[No Abstract] [Full Text] [Related]
16. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
18. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
19. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
20. A case of bullous dermatitis induced by erlotinib.
Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]